Europe
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
An investigational asthma treatment, tezepelumab, under development by Amgen and AstraZeneca failed to reduce asthma patients’ dependence on corticosteroids.
The U.S. Food and Drug Administration has approved several drugs and medical devices in the last week. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
Myovant’s oral Orgovyx beat out Abbvie’s injectable Lupron in achieving medical castration levels in patients. Here is the timeline of the approval.
The FDA put a clinical hold on UniQure’s Phase III trial after a high-risk participant developed liver cancer.
A new and more easily transmissible strain of COVID-19, dubbed VUI-202012/01, has now been reported in at least six different countries and global territories since it first appeared in the U.K. a few weeks ago.
The company bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios in a deal worth up to $2 billion.
AB Science SA reported promising data from its Phase IIb/III trial of masitinib in patients with confirmed mild to moderate Alzheimer’s disease.
PRESS RELEASES